View this email in your browser

Special Edition: 25th Anniversary
CURE Epilepsy Discovery

CURE Epilepsy Discovery: Strides Made in the Understanding of Acquired Epilepsies by CURE Epilepsy Grantees

The work of Dr. Annamaria Vezzani and Dr. Teresa Ravizza is instrumental not only to understand why and how the brain generates and sustains seizures, but also to discover biomarkers that could predict if someone will have seizures, or how they may respond to a drug. The ultimate hope is that this work with CURE Epilepsy will lead to the ability to prevent or cure acquired epilepsies.

A subset of acquired epilepsies is called post-traumatic epilepsy (PTE), which develops in the months or years following a TBI.[2] TBI may be caused by blows to the head, blasts, penetrating head injuries, accidental falls, sports-related injuries, or motor vehicle accidents. It is currently not possible to predict who will develop PTE after a TBI.[3] Dr. Annamaria Vezzani, head of the Laboratory of Epilepsy and Therapeutic Strategies, Department of Acute Brain Injury at the Mario Negri Institute for Pharmacological Research in Milan, has been an important part of CURE Epilepsy’s efforts to understand acquired epilepsies for decades as an early (2002) and repeat (2015) grantee, and more recently, as part of the PTE Initiative. Dr. Vezzani’s work centers on the role of inflammation in epilepsy. Her work looks at neuroinflammation (i.e., the inflammatory response that is sustained by cells in the brain after insult or injury) and has shown that neuroinflammation can play an important role in the generation of seizures.[4] Through a study funded by CURE Epilepsy, Dr. Vezzani first studied a specific signaling pathway in the brain called interleukin-1 (IL-1) type 1 receptor/Toll-like receptor (IL-1R/TLR4). Her experiments in experimental animals showed that IL-1beta and an inflammatory molecule known as High Mobility Group Box 1 (HMGB1) are released from specific brain cells known as “glia” during seizures.[5] The levels of HMGB1 increased in the brain and the blood before animals developed epilepsy, and this increase in HMGB1 levels was maintained during the development of epilepsy.[6,7] These results gave her precise biological mechanisms that could be targeted to stop seizures.

Read More
Today's CURE Epilepsy Discovery has the ability to help the 65 million people worldwide
who are impacted by epilepsy every day.
And each one of those individuals has a story.
Hear Marc's story
Facebook
LinkedIn
Twitter
Instagram
YouTube
Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research. CURE Epilepsy is a non-profit 501(c)(3) tax-exempt organization.Our tax identification number is 36-4253176.
Copyright © 2022 CURE Epilepsy, All rights reserved.
In the past you provided CURE Epilepsy your email address. Occasionally, you will receive updates from us about epilepsy research and news.

Our mailing address is:
CURE Epilepsy
420 Wabash Ave, Ste 650
Chicago, IL 60611
Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.






This email was sent to [email protected]
why did I get this?    unsubscribe from this list    update subscription preferences
CURE Epilepsy · 420 Wabash Ave, Ste 650 · Chicago, IL 60611 · USA